-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21

Benzinga·11/12/2025 12:33:01
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.